Research records indexed for Octreotide
This page carries 12 of the 9,618 records that the literature query returned for Octreotide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 9,606 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Octreotide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| [<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study pmid:38851203 | 2024 | Clinical Trial, Phase III, Equivalence Trial | human trial | Not stated | Indexed as clinical trial, phase iii, equivalence trial. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Neuroendocrine Tumors; Intestinal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Organometallic Compounds. |
| <sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial pmid:34793718 | 2021 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Neuroendocrine Tumors; Digestive System Neoplasms; Organometallic Compounds; Octreotide; Antineoplastic Agents, Hormonal. |
| Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival pmid:26731483 | 2017 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Neuroendocrine Tumors; Stomach Neoplasms; Octreotide; Antineoplastic Agents, Hormonal; Disease-Free Survival. |
| Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial pmid:25644760 | 2015 | Comparative Study, Randomized Controlled Trial | human trial | Not stated | Indexed as comparative study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Hepatorenal Syndrome; Midodrine; Octreotide; Lypressin; Albumins. |
| Pasireotide versus octreotide in acromegaly: a head-to-head superiority study pmid:24423324 | 2014 | Comparative Study, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Adenoma; Acromegaly; Octreotide; Somatostatin; Antineoplastic Agents, Hormonal. |
| Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial pmid:25260838 | 2014 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Acromegaly; Peptides, Cyclic; Octreotide; Somatostatin; Human Growth Hormone. |
| Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study pmid:22119496 | 2011 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Carcinoid Tumor; Malignant Carcinoid Syndrome; Disease Progression; Sirolimus; Octreotide. |
| The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy pmid:20484441 | 2010 | Research Support, Non-U.S. Gov't | other | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Neuroendocrine Tumors; Pentetic Acid; Organometallic Compounds; Octreotide; Receptors, Somatostatin. |
| 90Y-edotreotide for metastatic carcinoid refractory to octreotide pmid:20194865 | 2010 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Carcinoid Tumor; Yttrium Radioisotopes; Octreotide; Disease-Free Survival; Drug Resistance, Neoplasm. |
| Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group pmid:19704057 | 2009 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Neuroendocrine Tumors; Intestinal Neoplasms; Liver Neoplasms; Abdominal Pain; Diarrhea. |
| Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study pmid:18779618 | 2008 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Islet Cell; Pancreatic Neoplasms; Sirolimus. |
| Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b pmid:18323556 | 2008 | Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase ii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Carcinoid Tumor; Gastrointestinal Neoplasms; Liver Neoplasms; Polyethylene Glycols; Octreotide. |
Where this page sits
Compound page: Octreotide. Class: Endocrine and immune signalling peptides.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 448601, Octreotide. PubChem, National Library of Medicine (2026). pubchem:448601
- Drugs@FDA application register query for this compound, 17 application(s) returned: ANDA216589, ANDA076330, ANDA203765, ANDA217860, NDA019667. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:octreotide
- Octreotide. The New England journal of medicine (1996). pmid:8532003
- Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. European journal of nuclear medicine (1993). pmid:8404961
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). pmid:19704057
- Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). pmid:18779618
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet (London, England) (2011). pmid:22119496
- <sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology (2021). pmid:34793718
- [<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet (London, England) (2024). pmid:38851203
- 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2007). pmid:17401086
- [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. European journal of nuclear medicine (2001). pmid:11585290
- Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Annals of surgery (2000). pmid:10973392
- Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (Baltimore, Md.) (1999). pmid:10347109
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.